• Targeting the untapped: validation of novel tumor-specific targets for Actinium-225 radiotherapeutics

• Bridging preclinical to clinical: translational studies to optimize efficacy and patient selection

• Addressing high unmet need: Leveraging alpha-emitters to overcome resistance mechanisms